Clinical Trials Browser

Phase 1 × OTHER × Interleukin-2 × Clear all

NCT06152809 2026-03-18

CIML NK Cells With Venetoclax for AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT06321484 2026-03-04

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms, Recurrence

NCT07443020 2026-03-02

RIOT 4B

Phase 1 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT04052334 2026-02-20

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Phase 1 Completed

9 enrolled 10 charts

Sarcoma

NCT06236425 2026-01-08

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05628883 2026-01-07

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1 Active not recruiting

Uveal Melanoma, Melanoma

NCT06138587 2026-01-02

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05681780 2025-12-04

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Phase 1 Terminated

Breast Neoplasms

NCT06047977 2025-07-16

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Phase 1 Recruiting

Lymphocytes

NCT03991741 2025-07-03

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Phase 1 Terminated

3 enrolled 9 charts

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis

NCT04643574 2025-02-14

NeoTIL in Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT03475134 2025-02-11

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Phase 1 Completed

Melanoma

NCT02926053 2024-11-22

TIL Therapy for Metastatic Renal Cell Carcinoma

Phase 1 Completed

5 enrolled 8 charts

Carcinoma, Renal Cell

NCT03546426 2024-10-01

MESOVAX

Phase 1 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

NCT03175679 2024-09-19

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Phase 1 Completed

10 enrolled 14 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01883297 2024-09-05

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Recurrence

NCT04165967 2024-04-10

BaseTIL

Phase 1 Completed

Melanoma

NCT00968760 2023-12-19

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06121557 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT06121570 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

20 enrolled 10 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT05895370 2023-06-08

GI-HPVT-01

Phase 1 Unknown

Uterine Cervical Neoplasms, Recurrence

NCT01493453 2023-04-19

CD19

Phase 1 Terminated

CD19 Positive Non-Hodgkin Lymphoma

NCT05798546 2023-04-04

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Phase 1 Unknown

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04630769 2023-04-03

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Phase 1 Completed

3 enrolled 13 charts

Ovarian Neoplasms

NCT01946373 2022-10-04

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Phase 1 Unknown

Melanoma

NCT04327037 2022-03-02

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01662804 2021-05-27

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Phase 1 Completed

Neuroblastoma

NCT03992326 2021-03-18

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor, Adult

NCT03213964 2021-03-12

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Recurrence

NCT01603212 2019-05-21

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Phase 1 Completed

Melanoma

NCT00002787 2019-05-06

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Phase 1 Completed

Multiple Myeloma

NCT02863913 2019-03-06

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Phase 1 Withdrawn

Invasive Bladder Cancer Stage IV

NCT02867332 2019-03-06

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Phase 1 Withdrawn

Carcinoma, Renal Cell

NCT02070406 2019-02-28

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Phase 1 Terminated

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00470015 2019-02-19

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Phase 1 Completed

Melanoma

NCT00952237 2018-04-25

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Phase 1 Completed

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03175705 2018-01-18

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02130869 2017-12-22

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Phase 1 Completed

Lymphoma, Neuroblastoma

NCT02118285 2017-12-05

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02482090 2017-08-16

TIL Therapy for Metastatic Ovarian Cancer

Phase 1 Completed

Ovarian Neoplasms

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT02845999 2016-07-27

NK-EGFR01

Phase 1 Completed

Gastrointestinal

Gastrointestinal Metastatic Cancer

NCT00002994 2016-06-28

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00673829 2016-06-17

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

Phase 1 Suspended

Breast Neoplasms

NCT00027807 2016-02-17

Biological Therapy in Treating Women With Stage IV Breast Cancer

Phase 1 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT01672450 2015-07-08

A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

Phase 1 Completed

Melanoma